RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to
placebo for the treatment of schizophrenia or schizoaffective disorder.